Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 3UNKNOWN 1OTHER_GOV 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 42Esophageal Neoplasms 24Stomach Neoplasms 21Rectal Neoplasms 15Carcinoma, Non-Small-Cell Lung 14Colorectal Neoplasms 12Neoplasms 10Lung Neoplasms 10Brain Neoplasms 10Triple Negative Breast Neoplasms 9Small Cell Lung Carcinoma 8Squamous Cell Carcinoma of Head and Neck 7Neoplasm Metastasis 6Esophageal Squamous Cell Carcinoma 6Nasopharyngeal Carcinoma 5Lymphoma, Large B-Cell, Diffuse 5Carcinoma, Hepatocellular 5Recurrence 4Radiation Injuries 4Melanoma 4Lymphoma, Extranodal NK-T-Cell 4Head and Neck Neoplasms 4Uterine Cervical Neoplasms 3Meningeal Carcinomatosis 3Lymphoma 3Leukemia, Myeloid, Acute 3Hormone Receptor Positive Advanced Breast Cancer 3HER2-positive Breast Cancer 3Colonic Neoplasms 3Vomiting 2

Interventions

S 1 (combination) 1Docetaxel 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
UNKNOWN × Breast Cancer Recurrent × Clear all
NCT02947061 2016-10-31

S1 Plus Docetaxel Versus Capecitabine Plus Docetaxel First-line Treatment in Patients With Advanced Breast Cancer

ChineseAMS

Phase 2 Unknown
300 enrolled
Breast

Breast Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡